These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27984038)

  • 1. Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome.
    Boonk SE; Zoutman WH; Putter H; Ram-Wolff C; Felcht M; Klemke CD; Ranki A; Quaglino P; Whittaker S; Bagot M; Willemze R; Vermeer MH
    J Invest Dermatol; 2017 Mar; 137(3):754-757. PubMed ID: 27984038
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
    Michel L; Jean-Louis F; Begue E; Bensussan A; Bagot M
    Blood; 2013 Feb; 121(8):1477-8. PubMed ID: 23429988
    [No Abstract]   [Full Text] [Related]  

  • 3. T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression.
    Tang N; Gibson H; Germeroth T; Porcu P; Lim HW; Wong HK
    Br J Dermatol; 2010 Feb; 162(2):463-6. PubMed ID: 19995369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.
    Wong HK; Gibson H; Hake T; Geyer S; Frederickson J; Marcucci G; Caligiuri MA; Porcu P; Mishra A
    J Invest Dermatol; 2015 Aug; 135(8):2084-2092. PubMed ID: 25806852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
    Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma.
    Bégué E; Jean-Louis F; Bagot M; Jauliac S; Cayuela JM; Laroche L; Parquet N; Bachelez H; Bensussan A; Courtois G; Michel L
    Blood; 2012 Jul; 120(1):143-54. PubMed ID: 22627769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.
    Narducci MG; Arcelli D; Picchio MC; Lazzeri C; Pagani E; Sampogna F; Scala E; Fadda P; Cristofoletti C; Facchiano A; Frontani M; Monopoli A; Ferracin M; Negrini M; Lombardo GA; Caprini E; Russo G
    Cell Death Dis; 2011 Apr; 2(4):e151. PubMed ID: 21525938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLS3 expression and SMA phenotype: a commentary on correlation of PLS3 expression with disease severity in children with spinal muscular atrophy.
    Nishio H
    J Hum Genet; 2014 Feb; 59(2):64-5. PubMed ID: 24284364
    [No Abstract]   [Full Text] [Related]  

  • 10. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
    Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
    Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
    van Doorn R; Dijkman R; Vermeer MH; Out-Luiting JJ; van der Raaij-Helmer EM; Willemze R; Tensen CP
    Cancer Res; 2004 Aug; 64(16):5578-86. PubMed ID: 15313894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photopheresis does not improve survival in Sézary syndrome patients with bone marrow involvement.
    de Misa RF; Harto A; Azaña JM; Belmar P; Díez E; Ledo A
    J Am Acad Dermatol; 2005 Jul; 53(1):171-2. PubMed ID: 15965446
    [No Abstract]   [Full Text] [Related]  

  • 14. Aberrant expression of T-plastin in Sezary cells.
    Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
    Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells.
    Sugimachi K; Yokobori T; Iinuma H; Ueda M; Ueo H; Shinden Y; Eguchi H; Sudo T; Suzuki A; Maehara Y; Mori M; Mimori K
    Ann Surg Oncol; 2014 Oct; 21(11):3680-90. PubMed ID: 24217791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
    Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome.
    Cristofoletti C; Bresin A; Caprini E; Russo G; Narducci MG
    Cell Cycle; 2019 Jun; 18(11):1292-1294. PubMed ID: 31106661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
    Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
    J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
    Wong HK
    Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.